Omnicell, Inc. (OMCL) PT Raised to $52.00
Omnicell, Inc. (NASDAQ:OMCL) had its price target increased by Craig Hallum from $46.00 to $52.00 in a research report sent to investors on Friday, The Fly reports. Craig Hallum currently has a buy rating on the stock.
Several other research analysts have also recently issued reports on OMCL. Zacks Investment Research upgraded shares of Omnicell from a sell rating to a hold rating in a report on Tuesday, July 4th. CIBC increased their price target on shares of Omnicell from $43.00 to $53.00 and gave the stock an outperform rating in a research note on Wednesday, April 26th. TheStreet cut shares of Omnicell from a b- rating to a c+ rating in a research note on Thursday, May 4th. Piper Jaffray Companies cut shares of Omnicell from an overweight rating to a neutral rating and set a $40.00 price target for the company. in a research note on Friday, April 21st. Finally, Oppenheimer Holdings, Inc. reiterated an outperform rating and set a $53.00 price target (up previously from $43.00) on shares of Omnicell in a research note on Tuesday, April 25th. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company currently has a consensus rating of Buy and an average price target of $49.00.
Shares of Omnicell (OMCL) traded down 0.20% during midday trading on Friday, reaching $49.50. 58,660 shares of the company’s stock traded hands. Omnicell has a 1-year low of $30.35 and a 1-year high of $49.90. The stock’s market capitalization is $1.84 billion. The firm’s 50-day moving average price is $43.49 and its 200 day moving average price is $40.22.
Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Thursday, July 27th. The company reported $0.02 EPS for the quarter, hitting the consensus estimate of $0.02. Omnicell had a negative net margin of 1.14% and a positive return on equity of 0.41%. The company had revenue of $180.90 million during the quarter, compared to analysts’ expectations of $174.08 million. During the same quarter in the previous year, the business posted $0.38 EPS. The firm’s revenue was up 4.6% on a year-over-year basis. On average, equities analysts predict that Omnicell will post $1.28 earnings per share for the current fiscal year.
In other news, Chairman Randall A. Lipps sold 37,500 shares of the stock in a transaction dated Friday, July 28th. The shares were sold at an average price of $46.00, for a total value of $1,725,000.00. Following the completion of the transaction, the chairman now owns 196,551 shares in the company, valued at approximately $9,041,346. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman Randall A. Lipps sold 9,900 shares of the stock in a transaction dated Monday, June 5th. The shares were sold at an average price of $43.00, for a total transaction of $425,700.00. Following the completion of the transaction, the chairman now owns 208,982 shares of the company’s stock, valued at approximately $8,986,226. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 120,300 shares of company stock valued at $5,199,801. 3.77% of the stock is owned by insiders.
Several institutional investors have recently made changes to their positions in OMCL. Monroe Bank & Trust MI increased its stake in shares of Omnicell by 0.3% in the first quarter. Monroe Bank & Trust MI now owns 34,831 shares of the company’s stock worth $1,416,000 after buying an additional 116 shares during the period. State of Alaska Department of Revenue increased its stake in shares of Omnicell by 3.0% in the first quarter. State of Alaska Department of Revenue now owns 4,080 shares of the company’s stock worth $165,000 after buying an additional 120 shares during the period. Texas Permanent School Fund increased its stake in shares of Omnicell by 0.5% in the first quarter. Texas Permanent School Fund now owns 26,756 shares of the company’s stock worth $1,088,000 after buying an additional 122 shares during the period. Municipal Employees Retirement System of Michigan increased its stake in shares of Omnicell by 2.6% in the first quarter. Municipal Employees Retirement System of Michigan now owns 8,340 shares of the company’s stock worth $339,000 after buying an additional 210 shares during the period. Finally, 1st Global Advisors Inc. increased its stake in shares of Omnicell by 3.4% in the first quarter. 1st Global Advisors Inc. now owns 7,828 shares of the company’s stock worth $318,000 after buying an additional 255 shares during the period. Institutional investors and hedge funds own 96.35% of the company’s stock.
Omnicell Company Profile
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.